Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $50,526.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 3,609 shares of Centessa Pharmaceuticals stock in a transaction on Friday, April 25th. The stock was sold at an average price of $14.00, for a total transaction of $50,526.00. Following the transaction, the general counsel now owns 105,386 shares in the company, valued at approximately $1,475,404. This trade represents a 3.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Centessa Pharmaceuticals Trading Down 1.5 %

Shares of CNTA stock opened at $13.50 on Friday. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock has a 50 day simple moving average of $14.22 and a two-hundred day simple moving average of $15.81. The company has a market cap of $1.80 billion, a P/E ratio of -8.82 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.04. Research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its stake in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $171,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CNTA. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 target price for the company. Finally, Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $27.71.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.